Profile
NCNA NVO VRTX REGN SGEN ARGX
Company Name NuCana plc Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $4.08M $372.46B $106.01B $74.66B $43.15B $40.18B
Employees 0.03K 71.88K 5.40K 14.17K 3.26K 1.15K
CEO Mr. Hugh Stephen Griffith Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
NCNA NVO VRTX REGN SGEN ARGX
Quant Rating Score 2 3 3 3 3 1
Quant Rating Sell Neutral Neutral Neutral Neutral Strong Sell
Trading
NCNA NVO VRTX REGN SGEN ARGX
Last Close $1.04 $81.18 $411.66 $690.87 $228.74 $665.6
High 52 $9.7 $146.91 $516.74 $1201.76 $228.74 $670.4
Low 52 $0.18 $81.18 $392.81 $690.87 $228.74 $356.01
Price vs. 52 Week High -89.28 % -44.74 % -20.34 % -42.51 % 0 % -0.72 %
Price vs. 52 Week Low 477.78 % 0 % 4.8 % 0 % 0 % 86.96 %
Total Return
NCNA NVO VRTX REGN SGEN ARGX
1 Month Return -18.11 % -24.1 % -11.23 % -5.53 % 0 % 9.62 %
3 Month Return -44.68 % -31.09 % -15 % -32.04 % 0 % 22.19 %
6 Month Return -66.45 % -42.58 % -16.13 % -36.16 % 0 % 44.09 %
9 Month Return 484.27 % -34.48 % 3.6 % -23.11 % 0 % 76.9 %
YTD Return -12.61 % -5.63 % 2.22 % -3.01 % 0 % 8.23 %
1 Year Return 247.94 % -24.24 % -5.02 % -25.97 % 0 % 78.13 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
NCNA NVO VRTX REGN SGEN ARGX
Dividend Yield Percentage (TTM) - 1.66 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -34.63 % 1.25 % -2.62 % 4.88 % -2.27 % -2.22 %
Dividend Per Share (TTM) - 9.9 % - - - -
Payout Ratio (TTM) - 46.6 % - - - -
Growth
NCNA NVO VRTX REGN SGEN ARGX
Asset Growth -52.26 % 30.35 % 25.23 % 13.23 % -1.21 % 44.93 %
Gross Profit Growth - 32.32 % 9.64 % 6.49 % 22.93 % 190.7 %
Revenue Growth - 31.26 % 10.51 % 7.76 % 24.65 % 198.56 %
Revenue 3 Year - 90.03 % 60.36 % 55.67 % 91.56 % 2071.96 %
Revenue 5 Year - 123.63 % 219.55 % 110.3 % 215.48 % 3041.46 %
Revenue 10 Year - 65.69 % 610.45 % 549.62 % 494.04 % 9009.53 %
EBIT Growth 16.2 % 37.11 % 0 % -14.6 % 10.13 % 40.94 %
Net Income Growth 13.71 % 50.71 % 8.96 % -8.87 % 9.51 % 58.42 %
Net Income 3 Yeari Growth Per Share 35.23 % 106.26 % 34.59 % 13.48 % -763.59 % 64.01 %
Net Income 5 Yeari Growth Per Share -21.19 % 133.27 % 70.33 % 74.02 % -276.93 % -143.65 %
Net Income 10 Yeari Growth Per Share -262333.06 % 98.1 % 809.6 % 871.12 % -624.16 % -857 %
Operating Income Growth 16.2 % 37.11 % 0 % -14.6 % 10.13 % 40.94 %
Operating Cash Flow Growth (CFG) -14.17 % 38.06 % -14.35 % -8.39 % 9.07 % 51.28 %
Operating 3 Year CFG 12.04 % 117.73 % 9.63 % 76.95 % -147.99 % 21.71 %
Operating 5 Year CFG -31.29 % 162.84 % 174.78 % 125.17 % -195.86 % -329.63 %
Operating 10 Year CFG -295451.3 % 150.28 % 6084.35 % 713.56 % -2622.09 % -1280.2 %
EPS Growth 15.19 % 51.88 % 8.33 % -8.54 % 10.81 % 60.46 %
EPS Diluted Growth 14.42 % 52.37 % 8.35 % -9.03 % 10.81 % 60.46 %
Book Value Per Share -62.02 % 28.67 % 25.58 % 15.03 % -9.83 % 38.53 %
Share Holder 3 Year Equity Growth Per Share -89.21 % 74.77 % 104.06 % 137.56 % 33.72 % 93.75 %
Share Holder 5 Year Equity Growth Per Share -88.92 % 121.34 % 291.14 % 219.1 % 220.81 % 318.81 %
Share Holder 10 Year Equity Growth Per Share 25194.39 % 49.24 % 1030.79 % 1286.9 % 691.19 % 3654.06 %
Dividend Per Share Growth - 26.56 % - - - -
Dividend 3 Year Growth Per Share - 63.98 % - - - -
Dividend 5 Year Growth Per Share - 79.57 % - - - -
Dividend 10 Year Growth Per Share - 94.94 % - - - -
Debt Growth -38.03 % 4.74 % 44.1 % 0.06 % -23.28 % 60.95 %
Free Cash Flow Growth -13.69 % 9.17 % -16.47 % -17.11 % 3.67 % 51.98 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
NCNA NVO VRTX REGN SGEN ARGX
Gross Profit Margin TTM - 84.66 % 86.1 % 84.42 % 72.37 % 86.82 %
Return on Assets TTM -133.1 % 23.83 % -2.16 % 12.43 % -11.76 % -2.13 %
Return on Equity TTM -313.58 % 86.4 % -2.88 % 16.85 % -16.53 % -2.75 %
Return on Capital Employed TTM -688.19 % 62.74 % -1.72 % 11.85 % -16.87 % -8.98 %
Net Income Per EBT TTM 84.88 % 79.43 % -184.82 % 93.66 % 100.55 % 167.72 %
EBT Per Ebit TTM 98.65 % 100.52 % -82.68 % 124.1 % 94.01 % 15.76 %
EBIT Per Revenue TTM - 43.84 % -2.96 % 28.92 % -36.09 % -17.08 %
Cash Flow To Debt Ratio TTM -5312.22 % 207.5 % -49.48 % 157.08 % -185.98 % -428.57 %
Receivables Turnover TTM - 3.89 6.06 2.27 1.98 3.45
Payables Turnover TTM - 1.72 3.73 4.34 1.54 1.06
Inventory Turnover TTM - 1.09 1.37 0.71 0.65 0.91
Fixed Asset Turnover TTM - 225.8 % 422.11 % 311.93 % 256.83 % 6116.64 %
Asset Turnover TTM - 68.08 % 47.71 % 36.98 % 34.46 % 47.09 %
Operating Cash Flow Per Share TTM -5.4 26.54 -3.27 39.29 -1.12 -2.42
Free Cash Flow Per Share TTM -5.56 15.14 -4.51 31.25 -1.62 -3.52
Cash Per Share TTM 522.58 % 1681.33 % 2528.88 % 9062.44 % 657.5 % 5163.05 %
Operating Cash Flow Sales Ratio TTM - 43.69 % -7.94 % 30.67 % -16.85 % -6.44 %
Free Cash Flow Operating Cash Flow Ratio TTM 102.89 % 57.03 % 138.12 % 79.52 % 144.14 % 145.12 %
Cash Flow Coverage Ratios TTM -5312.22 % 207.5 % -49.48 % 157.08 % -185.98 % -428.57 %
Price To Free Cash Flows Ratio TTM -0.28 40.13 -91.09 22.11 -141.85 -190.24
Price To Operating Cash Flows Ratio TTM -0.16 22.42 -126.05 17.58 -203.89 -274.79
Price Cash Flow Ratio TTM -0.16 22.42 -126.05 17.58 -203.89 -274.79
Income Statement (TTM)
NCNA NVO VRTX REGN SGEN ARGX
Revenue $0B $232.26B $9.87B $13.12B $1.96B $1.23B
Gross Profit $0B $196.5B $8.61B $11.3B $1.55B $1.11B
Gross Profit Ratio 0% 84.6% 87.21% 86.16% 79.1% 90.39%
EBITDA $-0.03B $113.33B $4.61B $4.69B $-0.62B $-0.22B
Net Income $-0.03B $83.68B $3.62B $3.95B $-0.61B $-0.3B
EPS Diluted -13.12 9.31 13.89 34.77 -3.3 -5.16
Balance Sheet (MRQ)
NCNA NVO VRTX REGN SGEN ARGX
Long Term Debt $0B $20.53B $0.72B $2.7B $0.04B $0.02B
Total Liabilities $0.01B $207.93B $5.15B $7.11B $0.87B $0.44B
Total Equity $0.01B $106.56B $17.58B $25.97B $2.8B $4.1B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $1.18B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $0.02B
Total Assets $0.03B $314.49B $22.73B $33.08B $3.67B $4.54B
Cash Flow Statement (TTM)
NCNA NVO VRTX REGN SGEN ARGX
Net Income $-0.03B $83.68B $3.62B $3.95B $-0.61B $-0.43B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $-0.08B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.03B $108.91B $3.54B $4.59B $-0.45B $-0.42B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.04B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.995
ABCL AbCellera Biologics Inc. 2.77
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.09
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.56
ABPWW 0.0652
ABSI Absci Corporation 2.71
ABUS Arbutus Biopharma Corporation 3.18
ABVC ABVC BioPharma, Inc. 0.5157
ABVX Abivax SA American Depositary Shares 6.15
ACAD ACADIA Pharmaceuticals Inc. 16.9
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.9092
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.17
ACHV Achieve Life Sciences, Inc. 3.15
ACIU AC Immune SA 2.61
ACLX Arcellx, Inc. 64.65
ACRV Acrivon Therapeutics, Inc. Common Stock 5.56
Unlock